The University of Alicante is participating in the largest scientific assessment driven to date by the United Nations to analyse the health of the world's oceans. This international project brings together hundreds of specialists from across the globe and currently serves as the primary global benchmark for guiding marine conservation policies internationally.

The American College of Medical Genetics and Genomics (ACMG) has published a new statement providing evidence-based recommendations for the reporting and communication of variants of uncertain significance (VUS) in germline genetic and genomic testing. Published in Genetics in Medicine, the guidance is intended to promote greater consistency, transparency, and best practices among laboratories and healthcare professionals as genetic testing becomes increasingly integrated into patient care.

With the Lecture Series on Cancer Breakthroughs, Gustave Roussy and The Lancet are joining forces to create a high-level annual international event dedicated to major scientific advances that are transforming—or will transform—the lives of patients at increased risk of cancer or living with the disease. These lectures aim to accelerate the dissemination of innovation and the sharing of knowledge for the benefit of patients worldwide. The inaugural lecture, to be held on 18 September in France and online, will focus on personalised cancer prevention. This first Lecture will be chaired by a distinguished guest, Professor Timothy R. Rebbeck, Professor at the Harvard T.H. Chan School of Public Health and the Dana-Farber Cancer Institute.

Researchers at NYU College of Dentistry have uncovered what may be biologically driving oral health issues unique to Down syndrome.

 

Their study, published in Cell Reports, describes a molecular mechanism—a defect in calcium signaling—behind low saliva production, along with other factors that may contribute to gum disease.

New research published in Nature is first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor, with peripheral biomarker changes and associated tumor biology. HIF-2a inhibition with casdatifan resulted in deep and sustained suppression of the hormone erythropoietin in blood (serum EPO), which correlated with higher response rates and longer progression-free survival (PFS). A pooled analysis from four monotherapy cohorts (n=121) of the ARC-20 study showed that advanced kidney cancer patients treated with casdatifan lived beyond a year without cancer progression (median PFS of 12.2 months) despite multiple prior treatments with other standard regimens.